Duyvesteyn H.M.E.
183
Coauthors
5
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Inmunología | 10 |
| Biotecnología | 3 |
| Bioquímica | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Microorganismos, hongos y algas | 5 |
| Enfermedades | 2 |
| Medicina y salud | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 5 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Townsend A.R. | 5 |
| James W.S. | 5 |
| Javier Gilbert Jaramillo | 5 |
| Carroll M.W. | 5 |
| Tan T.K. | 5 |
| Stuart D.I. | 5 |
| Zhou D. | 5 |
| Zhao Y. | 5 |
| Ren J. | 5 |
| Rijal P. | 4 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
ArticleAbstract: Background: Administration of potent anti-receptor-binding domain (RBD) monoclonal antibodies has bePalabras claves:Antibody cocktail, Antibody-antigen complex, Human monoclonal antibody, In vitro and in vivo function, Receptor-binding domain epitope, SARS-COV-2Autores:Buttigieg K.R., Carroll M.W., Charlton S., Chen C., Chen C.P., Chen X., Cheng S.H., Donat R.F., Duyvesteyn H.M.E., Fry E.E., Ginn H.M., Harding A.C., Huang K.Y.A., James W.S., Javier Gilbert Jaramillo, Lien C.E., Lin M.Y., Lin T.Y., Ma C., Qin L., Ren J., Rijal P., Schimanski L., Stuart D.I., Tan T.K., Townsend A.R., Tree J.A., Zhao Y., Zhou D.Fuentes:scopusAuthor Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 (Nature Structural & Molecular Biology, (2020), 27, 9, (846-854), 10.1038/s41594-020-0469-6)
OtherAbstract: In the version of this article initially published, author Jiandong Huo’s name was spelt incorrectlyPalabras claves:Autores:Bas A.L., Buttigieg K.R., Carrique L., Carroll M.W., Clare D.K., Coombes N., Dumoux M., Duyvesteyn H.M.E., Elmore M.J., Harrison P.J., Huo J., James W.S., Javier Gilbert Jaramillo, Knight M.L., Malinauskas T., Mikolajek H., Moynié L., Naismith J.H., Owens R.J., Radecke J., Ren J., Rijal P., Ruza R.R., Shah P.N.M., Stuart D.I., Tan T.K., Townsend A.R., Tree J.A., Vogirala V.K., Ward P.N., Weckener M., Zhao Y., Zhou D.Fuentes:scopusNeutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
ArticleAbstract: The SARS-CoV-2 virus is more transmissible than previous coronaviruses and causes a more serious illPalabras claves:Autores:Buttigieg K.R., Carrique L., Carroll M.W., Clare D.K., Coombes N., Dumoux M., Duyvesteyn H.M.E., Elmore M.J., Harrison P.J., Huo J., James W.S., Javier Gilbert Jaramillo, Knight M.L., Le Bas A., Malinauskas T., Mikolajek H., Moynié L., Naismith J.H., Owens R.J., Radecke J., Ren J., Rijal P., Ruza R.R., Shah P.N.M., Stuart D.I., Tan T.K., Townsend A.R., Tree J.A., Vogirala V.K., Ward P.N., Weckener M., Zhao Y., Zhou D.Fuentes:scopusStructural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
ArticleAbstract: The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently noPalabras claves:Autores:Buttigieg K.R., Carrique L., Carroll M.W., Chen C.P., Chen T.H., Cheng C.Y., Cheng S.H., Donat R.F., Duyvesteyn H.M.E., Fry E.E., Godwin K., Huang C.G., Huang K.Y.A., Huang Y.C., Huo J., James W.S., Javier Gilbert Jaramillo, Knight M.L., Lin T.Y., Lin Y.C., Ma C., Malinauskas T., Mongkolsapaya J., Naismith J.H., Owens R.J., Paterson N.G., Radecke J., Ren J., Rijal P., Ruza R.R., Screaton G.R., Shah P.N.M., Shih S.R., Stuart D.I., Supasa P., Tan T.K., Townsend A.R., Tree J.A., Zhao Y., Zhou D.Fuentes:scopusThe antigenic anatomy of SARS-CoV-2 receptor binding domain
ArticleAbstract: Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency use as therapPalabras claves:coronavirus, SARS-CoV-2, anti-RBD antibody, receptor binding domain, antibody, immune responses, virus structureAutores:Bailey A.L., Bertram F.K.R., Bolton J., Carroll M.W., Case J.B., Chen R.E., Clare D.K., Dejnirattisai W., Diamond M.S., Dold C., Dong T., Duyvesteyn H.M.E., Fry E.E., Fyfe A., Ginn H.M., Gupta S., Hall D.R., Howe A., Huang K.Y.A., James W.S., Javier Gilbert Jaramillo, Kafai N.M., Klenerman P., Knight J.C., Knight M.L., Levin R., Liu C., López-Camacho C., Mentzer A.J., Mongkolsapaya J., Paesen G.C., Paterson N.G., Peng Y., Pollard A.J., Radecke J., Ren J., Screaton G.R., Siebert C.A., Skelly D.T., Slon-Campos J., Song Y., Stuart D.I., Supasa P., Tan T.K., Temperton N.J., Thompson C., Townsend A.R., Walter T.S., Wang B., Williams M.A., Ying B., Zhao Y., Zhou D.Fuentes:scopus